Treatment and evaluation of CLL: A complicated affair

Blood

Volumn 107, Issue 3, 2006, Pages 848-

  Kay, Neil E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOMODULATING AGENT; PENTOSTATIN; PURINE NUCLEOSIDE; PURINE NUCLEOSIDE DERIVATIVE;

CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 31544433388     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-11-4501     Document Type: Short Survey

References (5)

1. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood. 2004;103:1202-1210.
2. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
3. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
4. Kay NE, Geyer SM, Lin T, et al. Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [abstract]. Blood. 2004;104:100a. Abstract 339.
5. Finn IW, Grever MR, Neuberg D, et al. Fludarabine and cyclophosphamide produces a significantly higher response rate and more durable remissions than fludarabine in patients with previously untreated CLL [abstract]. Blood. 2004;104:139a. Abstract 475.